Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03430895
Title	Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Memorial Sloan Kettering Cancer Center
Indications	bladder adenocarcinoma urethra cancer bladder squamous cell carcinoma renal pelvis squamous cell carcinoma bladder carcinoma urethra squamous cell carcinoma ureter small cell carcinoma urachus cancer ureter carcinoma ureter adenocarcinoma urethra adenocarcinoma renal pelvis carcinoma renal pelvis adenocarcinoma
Therapies	Durvalumab + Tremelimumab
Age Groups:	senior \| adult
Covered Countries	USA